Lysodren Oral
Generic Name: MITOTANE - ORAL
Pronounced: (MY-toe-tain)
Lysodren Oral Uses
Mitotane is used to treat cancer of the adrenal glands.
The adrenal glands produce hormones, which are needed by the body to deal with
stress, fight infection, and maintain normal functions such as blood pressure.
Certain cancers cause the adrenal glands to produce too much cortisol and other
hormones, causing a certain serious condition (Cushing's syndrome). Too much of
these hormones can cause many problems such as blood pressure changes, weight
changes, muscle/bone weakness, thinning skin, and diabetes. Mitotane works by
killing or slowing the growth of adrenal gland cells and also reverses the side
effects caused by too much hormone production.
How To Use Lysodren Oral
Take this medication by mouth with or without food,
usually 3 or 4 times daily or as directed by your doctor. This medication is
often started in the hospital, where your doctor can follow you closely as your
dose is adjusted to the best dose for you. Dosage is based on your medical
condition and response to therapy (e.g., cortisol levels).
Usually, you will need to take replacement corticosteroids
(e.g., hydrocortisone) every day while you are taking this drug and for some
time after stopping mitotane.
Use this medication regularly to get the most benefit from
it. To help you remember, take it at the same times each day. Do not increase
your dose or take this medication more often than prescribed. Your condition
will not improve any faster, and the risk of serious side effects may be
increased.
It may take up to several months to receive the full
benefit from this drug. Inform your doctor if your condition persists or
worsens.
Since this drug can be absorbed through the skin and
lungs, women who are pregnant or who may become pregnant should not handle this
medication or breathe the dust from the tablets. Learn proper technique for
safe handling and disposal of this medicine and its container. Consult your
pharmacist.
| 
Email this page
Printer friendly
Bookmark this page
